Severity
Moderate
ModerateClass IITerminated
FDA Drug recall · Reported February 12, 2014
Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89 (carton) and 00182-0554-00 (single blister).
Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
Teva Pharmaceuticals USA recalled Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Re… - a moderate-severity action.
Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Re… was recalled by Teva Pharmaceuticals USA in February 12, 2014. Reason: Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification …. Check the official notice for the remedy. Verify recall #D-1074-2014 with the FDA Drug before acting.
The recall
Teva Pharmaceuticals USA issued this moderate-severity FDA Drug recall-Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification ….
- Moderate
- severity level
- Class II
- classification
- February 12, 2014
- reported
Sourced from official FDA Drug enforcement records. Verify recall #D-1074-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
Recall Insight
This FDA Drug action (record #D-1074-2014) was formally reported on February 12, 2014, with the manufacturer initiating the action on December 18, 2013. It is classified under Moderate severity (Class II), with a current status of Terminated. Teva Pharmaceuticals USA is listed as the recalling firm, operating out of Horsham, PA. Federal records list the affected scope as 1,249,700 tablets.
The documented reason for this recall is: Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Household Products recalls over time
Where this recall sits in its category - 3,056 household products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Affected scope
1,249,700 tablets
Related Recalls
6
0 from same agency
Product description
Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89 (carton) and 00182-0554-00 (single blister).
Reason for recall
Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
Recall Profile
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1074-2014 |
| Date reported | February 12, 2014 |
| Date initiated | December 18, 2013 |
| Recalling firm | Teva Pharmaceuticals USA |
| Firm location | Horsham, PA |
| Affected scope | 1,249,700 tablets |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
- Check the recall number (D-1074-2014) and product description against the item you own. Search the archive
- Confirm the current status with FDA Drug before acting, recall details can be updated.
- Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Frequently Asked Questions
What product was recalled? ▼
Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89 (carton) and 00182-0554-00 (single blister).. Recalled by Teva Pharmaceuticals USA. Units affected: 1,249,700 tablets.
Why was this product recalled? ▼
Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on February 12, 2014. Severity: Moderate. Recall number: D-1074-2014.
Where was the recalled product distributed? ▼
Distribution: Nationwide.
How do I check if my product is affected by a recall? ▼
Check the product description and recall number (D-1074-2014) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device? ▼
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.
Nearby Recalls in This Category
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
CPSC Moderate
Cooper Lighting Recalls Metalux Optimized High Bay LED Light Fixtures Due to Fire Hazard
Cooper Lighting, LLC, of Peachtree City, Georgia · 2026-07-02
CPSC Moderate
Winco Fireworks International Recalls Roman Candles 8 Shot Fireworks Due to Risk of Serious Injury from Explosion and B…
· 2026-07-02
CPSC Moderate
Winco Fireworks International Recalls Unity 7 Shot 200 Gram Aerial Cake Fireworks Due to Risk of Serious Injury from Ex…
· 2026-07-02
CPSC Moderate
Kith Retail Recalls Children's Loungewear Sets Due to Risk of Serious Injury from Burn Hazard; Violate Mandatory Standa…
· 2026-06-25
CPSC Moderate
Southern Telecom Expands Recall of Lomi Waxing Kits Due to Risk of Serious Injury or Death from Fire and Burn Hazards; …
· 2026-06-25
Compare this recall with Cooper Lighting Recalls Metalux Optimized High Bay LED Ligh… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 12, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.